Tag Archives: Jay Olson

Portola Pharma (PTLA) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on Portola Pharma (PTLA – Research Report) today and set a price target of $42. The company’s shares opened today at $32.06. Olson noted: “PTLA reported 1Q results roughly in line with

Oppenheimer Keeps Their Buy Rating on SAGE Therapeutics (SAGE)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $170. The company’s shares closed on Friday at $167.34, close to its 52-week high of

SAGE Therapeutics (SAGE) Receives a Buy from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) yesterday and set a price target of $170. The company’s shares closed yesterday at $165.52, close to its 52-week high of $177.14. Olson said: “SAGE

Amgen Inc (AMGN) Receives a Buy from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on Amgen Inc (AMGN – Research Report) yesterday and set a price target of $220. The company’s shares closed yesterday at $179.32. Olson observed: “1Q results included non-GAAP EPS of $3.56, ahead

Oppenheimer Keeps Their Buy Rating on Portola Pharma (PTLA)

Oppenheimer analyst Jay Olson maintained a Buy rating on Portola Pharma (PTLA – Research Report) today and set a price target of $42. The company’s shares opened today at $35.51. Olson said: “We examine several frequently asked questions in anticipation

Oppenheimer Reaffirms Their Hold Rating on Incyte Corp (INCY)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Hold rating on Incyte Corp (INCY – Research Report), with a price target of $85. The company’s shares closed on Friday at $84.76, close to its 52-week high of